MedTrace Logo

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

NCT05584709 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-01-30

No results posted yet for this study

Summary

This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any advanced solid tumor.

The patients that will be treated with STI-6129 in this trial are advanced solid tumor patients who have received prior lines of treatment.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

STI-6129

Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).

Sponsors & Collaborators

  • Sorrento Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2025-08-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584709 on ClinicalTrials.gov